In recent trading session, Trevi Therapeutics Inc (NASDAQ:TRVI) saw 0.43 million shares changing hands at last check today with its beta currently measuring 0.93. Company’s recent per share price level of $4.70 trading at $0.13 or 2.84% at last check today assigns it a market valuation of $420.02M. That most recent trading price of TRVI’s stock is at a premium of 0.43% from its 52-week high price of $4.68 and is indicating a premium of 51.06% from its 52-week low price of $2.30.
For Trevi Therapeutics Inc (TRVI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.10. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Upright in the green today for gaining 2.84%, in the last five days TRVI remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $4.70 price level, adding 1.67% to its value on the day. Trevi Therapeutics Inc’s shares saw a change of 14.08% in year-to-date performance and have moved 16.05% in past 5-day. Trevi Therapeutics Inc (NASDAQ:TRVI) showed a performance of 32.21% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 21.67% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -27.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -27.66% for stock’s current value.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 27.24% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -67.11% while estimates for its earnings growth in next 5 years are of -24.56%.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
NEA MANAGEMENT COMPANY, LLC is the top institutional holder at TRVI for having 11.37 million shares of worth $33.88 million. And as of 2024-06-30, it was holding 11.4255 of the company’s outstanding shares.
The second largest institutional holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., which was holding about 7.38 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4169 of outstanding shares, having a total worth of $22.0 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 1.78 shares of worth $8.34 million or 2.31% of the total outstanding shares. The later fund manager was in possession of 1.52 shares on Nov 30, 2024, making its stake of worth around $7.13 million in the company or a holder of 1.97% of company’s stock.
